The Value of Using Mini-oral Pulse Steroid Therapy Along With Non Cultured Epidermal Cell Suspension (NCES) in Stable Resistant Vitiligo

Launched by CAIRO UNIVERSITY · May 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with vitiligo, a skin condition that causes loss of color in patches. Specifically, the trial will look at how well a mini-oral pulse steroid therapy works when combined with a procedure called non-cultured epidermal cell suspension (NCES) for patients whose vitiligo has not improved with regular treatments. The focus is on those with stubborn patches of vitiligo on difficult areas like the elbows and knees.

To participate in this trial, individuals must be at least 18 years old and have stable vitiligo for at least one year, meaning their condition has not changed during that time. They should have lesions in the hard-to-treat areas mentioned and should not have received any topical or systemic treatments for a certain period before the surgery. The trial is not yet recruiting participants, but it’s designed to offer hope for those who have struggled to find effective treatment for their vitiligo. Participants will have the chance to explore a potentially beneficial therapy that may help improve their skin color.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with non-segmental vitiligo (NSV) with acral or resistant lesions over the elbows and knees, that has not responded to conventional treatment
• • Stability for ≥ 1 year
• • Age ≥18 years
• • Lack of topical treatment for at least 1 month prior to surgery and systemic treatment for at least 3 months prior to surgery.
• Exclusion Criteria:
• • Non acral NSV responsive to conventional treatment modalities
• • Active vitiligo; new lesions, expansion of old lesions, confetti like lesions, ill-defined edges or koebnerization in \< 1 year
• • Age \< 18 years.
• • Pregnant females.
• • Patients with hypertension, diabetes or tuberculosis
• • Topical treatment in the past month and systemic treatment in the past 3 months.